122 results on '"Rampal, Raajit"'
Search Results
2. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
3. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
4. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
5. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis
6. Epo-IGF1R cross talk expands stress-specific progenitors in regenerative erythropoiesis and myeloproliferative neoplasm
7. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis
8. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation
9. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
10. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression
11. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
12. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
13. Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin
14. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
15. Survival following allogeneic transplant in patients with myelofibrosis
16. Clinical developments in epigenetic-directed therapies in acute myeloid leukemia
17. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
18. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
19. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
20. Oral idasanutlin in patients with polycythemia vera
21. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis
22. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
23. MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study
24. MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis
25. MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study
26. Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis
27. High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis
28. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
29. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
30. Moving toward disease modification in polycythemia vera
31. JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis
32. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
33. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
34. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
35. MPN-136 Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
36. MPN-153 A Phase 1b Trial of DISC-0974, an Antihemojuvelin Antibody, in Participants With Myelofibrosis and Anemia
37. Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With Pacritinib in the United States
38. MPN-386 Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With Pacritinib in the United States
39. MPN-135 Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
40. AML-385 A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
41. Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery
42. Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
43. A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Participants With Myelofibrosis and Anemia
44. A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
45. Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
46. Improvement in Individual Symptoms and Total Symptom Score (TSS) and Matching-Adjusted Indirect Comparison (MAIC) Analysis to Compare TSS As a Continuous Endpoint in Patients with Myelofibrosis Treated with Pelabresib in Combination with Ruxolitinib Versus Janus Kinase Inhibitor Monotherapy
47. Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119
48. Mylox-1: An Open-Label, Phase IIa Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral LOXL2 Inhibitor, GB2064, in Myelofibrosis
49. Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
50. Erythroid and Megakaryocytic Differentiation Program in JAK2-Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.